Pegfilgrastim-induced bone pain: Incidence, risk factors, and management in a community practice

Community Oncology

Volumn 4, Issue 7, 2007, Pages 455-458

  Kirshner, Jeffrey J ^a,c,d   Hickok, Jane ^b,e   Hofman, Maarten ^b  

^a Hematology Oncology Associates of Central New York Community Clinical Oncology Program (CCOP)   (United States)

^b UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^c HOACNY CCOP   (United States)

^d SUNY UPSTATE MEDICAL UNIVERSITY   (United States)

^e UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; NARCOTIC AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; PARACETAMOL; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

ADULT; AGED; ANALGESIA; ARTICLE; BONE PAIN; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER PATIENT; CONTROLLED STUDY; DIGESTIVE SYSTEM CANCER; DISEASE SEVERITY; FEMALE; HEALTH SURVEY; HUMAN; INCIDENCE; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; MEDICAL PRACTICE; QUALITY OF LIFE; RISK FACTOR;

EID: 34547145886     PISSN: 15485315     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1548-5315(11)70107-3     Document Type: Article

References (9)

1. Patterson KL, Masuda SY, Brown SL. Safety profile of filgrastim (r-metHuG-CSF). In: Morstyn G, Dexter TM, Foote MA, eds. Filgrastim (r-metHuG-CSF in Clinical Practice. Totowa, NJ: Humana Press; 1998:583-601.
2. Crawford J. Safety and efficacy of pegfilgrastim in patients receiving myelosuppressive chemotherapy. Pharmacotherapy 2003;23(8 pt 2):15S-19S.
3. Biganzoli L, Untch M, Skacel, Pico JL. Neulasta (pegfilgrastim): a once-per-cycle option for the management of chemotherapy-induced neutropenia. Semin Oncol 2004;31(3 suppl 8):27-34.
4. Citron M, Berry DA, Cirrincione C, et al. Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741. J Clin Oncol 2003;21:1431-1439.
5. Kummel S, Krocker J, Kohls A, et al. Randomised trial: survival benefit and safety of adjuvant dose-dense chemotherapy for node-positive breast cancer. Br J Cancer 2006;94:1237-1244.
6. Kubista E, Glaspy JA, Holmes FA, et al. Bone pain associated with once-per-cycle pegfilgrastim is similar to daily filgrastim in patients with breast cancer. Clin Breast Cancer 2003;3:391-398.
7. Heil G, Hoelzer D, Sanz MA, et al. A randomized, double-blind, placebo-controlled, phase I-II study of filgrastim in remission induction and consolidation therapy for adults with de novo acute myeloid leukemia. Blood 1997;90:4710-4718.
8. Kirshner JJ. Pegfilgrastim (N) induced bone pain (NIBP): incidence, risk factors and management in a community practice. J Clin Oncol 2006;24(18S):8598.
9. Lyman GH, Kuderer NM, Djulbegovic B. Prophylactic granulocyte colony-stimulating factor in patients receiving dose-intensive chemotherapy: a meta-analysis. Am J Med 2002;112:406-411.